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Metformin inhibits gluconeogenesis in AMPKα1α2-null (AMPK KO) mouse hepatocytes. After attachment, WT and AMPK-deficient primary 
hepatocytes were cultured for 16 hours in M199 medium containing 100 nM dex. Hepatocytes were then incubated in glucose-free DMEM con-
taining lactate/pyruvate (10:1 mM) and 100 nM dex alone or with 100 μM Bt2-cAMP and with or without 0.25, 0.5, 1, or 2 mM metformin. After 8 
hours, medium was collected for glucose measurement and cells were harvested for Western blot and gluconeogenic gene expression analyses. 
(A) Glucose production was normalized to protein content and presented as a percentage of glucose produced by WT hepatocytes incubated in 
the absence of both Bt2-cAMP and metformin. Results are representative of 5 independent experiments. (B) Immunoblots were performed against 
phospho-AMPKα (Thr172), AMPKα, phospho-ACC (Ser79), ACC, CRTC2, G6Pase, and PEPCK. Blots are representative of at least 5 indepen-
dent experiments. (C) Relative mRNA levels of Pgc-1α, Pepck, and G6Pase expressed as fold activation relative to levels in WT hepatocytes 
incubated in the absence of both Bt2-cAMP and metformin. Results are representative of 5 independent experiments. Data are mean ± SEM. 
§P < 0.001, ‡P < 0.001 compared with WT and AMPK-KO hepatocytes incubated without Bt2-cAMP; *P < 0.001, †P < 0.001 compared with WT and 
AMPK-KO hepatocytes incubated with Bt2-cAMP alone; #P < 0.01 compared with WT hepatocytes incubated under the same conditions.
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Effects of metformin on blood 
glucose levels in AMPKα1α2LS–/– 
mice. (A) Western blot analysis 
of AMPKα and PEPCK proteins 
in livers from 24-hour-fasted con-
trol and AMPKα1α2LS–/– mice. 
β-Actin was immunoblotted as a 
loading control. Each lane rep-
resents the liver sample from an 
individual mouse. (B) Plasma 
blood glucose levels were mea-
sured in fasted and fed control and 
AMPKα1α2LS–/– mice. n = 5–6. (C) 
Plasma insulin levels were mea-
sured in fasted and fed control 
and AMPKα1α2LS–/– mice. Data 
are mean ± SEM (n = 5–6). (D) 
Pyruvate tolerance tests (2 g/kg) 
in control and AMPKα1α2LS–/– mice 
were used to assess hepatic glu-
coneogenesis. n = 6–7. (E) Insu-
lin tolerance tests (0.25 U/kg) in 
control and AMPKα1α2LS–/– mice. 
n = 6–9. Metformin tolerance tests 
in control (F) and AMPKα1α2LS–/– 
(G) mice. Mice were given an 
oral gavage dose of 50, 150, or 
300 mg/kg metformin or vehicle 
and after 30 minutes challenged 
with an oral administration of 
glucose (3 g/kg body weight). 
n = 6–10. Data are mean ± SEM. 
*P < 0.05, **P < 0.005, 150 mg/kg 
metformin compared with vehicle 
control; #P < 0.01, ##P < 0.001, 
300 mg/kg compared with the 
vehicle control.
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Effects of AICAR on gluconeogenesis in WT and AMPK-KO hepatocytes. After attachment, WT and AMPK-deficient primary hepatocytes were 
cultured for 16 hours in M199 medium containing 100 nM dex. Hepatocytes were then incubated in glucose-free DMEM containing lactate/pyru-
vate (10:1 mM) and 100 nM dex, alone or with 100 μM Bt2-cAMP and with or without 125, 250, or 500 μM AICAR. After 8 hours, medium was 
collected for glucose measurement, and cells were harvested for Western blot and gluconeogenic gene expression analyses. (A) Glucose pro-
duction was normalized to protein content and expressed as a percentage of glucose production by WT hepatocytes incubated in the absence of 
both Bt2-cAMP and AICAR. Results are representative of 5 independent experiments. (B) Immunoblots were performed against phospho-AMPKα 
(Thr172), AMPKα, phospho-ACC (Ser79), ACC, CRTC2, and PEPCK. Blots are representative of at least 3 independent experiments. (C) Rela-
tive mRNA levels of Pgc-1α, Pepck, and G6Pase expressed as a percentage of WT hepatocytes incubated in the absence of both Bt2-cAMP and 
AICAR. Results are representative of 5 independent experiments. Data are mean ± SEM. §P < 0.01, ‡P < 0.01 compared with WT and AMPK-KO 
hepatocytes incubated without Bt2-cAMP; *P < 0.01, †P < 0.01 compared with WT and AMPK-KO hepatocytes incubated with Bt2-cAMP alone.
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Effects of A-769662 on gluconeogenesis in WT and AMPK-KO hepatocytes. After attachment, WT and AMPK-deficient primary hepatocytes were 
cultured for 16 hours in M199 medium containing 100 nM dex. Hepatocytes were then incubated in glucose-free DMEM containing lactate/pyruvate 
(10:1 mM) and 100 nM dex alone or with 100 μM Bt2-cAMP and with or without 1, 10, or 100 μM A-769662. After 8 hours, medium was collected 
for glucose measurement and cells were harvested for Western blot and gluconeogenic gene expression analyses. (A) Glucose production was 
normalized to protein content and expressed as a percentage of glucose production by WT hepatocytes incubated in the absence of both Bt2-cAMP 
and A-769662. Results are representative of 5 independent experiments. (B) Immunoblots were performed against phospho-AMPKα (Thr172), 
AMPKα, phospho-ACC (Ser79), ACC, CRTC2, and PEPCK. Blots are representative of least 5 independent experiments. (C) Relative mRNA levels 
of Pgc-1α, Pepck, and G6Pase expressed as fold activation relative to levels in WT hepatocytes incubated in the absence of both Bt2-cAMP and 
A-769662. Results are representative of 5 independent experiments. Data are mean ± SEM. §P < 0.01, ‡P < 0.01 compared with WT and AMPK-KO 
hepatocytes incubated without Bt2-cAMP; *P < 0.01, †P < 0.01 compared with WT and AMPK-KO hepatocytes incubated with Bt2-cAMP alone.
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Figure 
Metformin reduces energy state in primary hepatocytes and in liver of C57BL/6J mice. (A–E) After attachment, C57BL/6J mouse primary 
hepatocytes were cultured for 16 hours in M199 medium containing 100 nM dex. Hepatocytes were then incubated in glucose-free DMEM 
containing lactate/pyruvate (10:1 mM) and 100 nM dex alone or with 100 μM Bt2-cAMP and with or without 0.25, 0.5, 1, or 2 mM metformin. 
After 8 hours, medium was collected for glucose measurement and cells were harvested for measurement of adenine nucleotide content. (A) 
ATP, ADP, and AMP content in hepatocytes, (B) AMP/ATP ratios, and (C) total adenine nucleotide content are shown for each condition. (D) 
Glucose production was normalized to protein content and presented as a percentage of glucose produced by hepatocytes incubated in the 
absence of both Bt2-cAMP and metformin. (E) Correlation between glucose production and ATP content shown in D and A, respectively. Results 
are representative of 3 independent experiments. *P < 0.05, **P < 0.01, §P < 0.005, §§P < 0.001 compared with hepatocytes incubated in the 
absence of both Bt2-cAMP and metformin; †P < 0.05, ††P < 0.01, #P < 0.005, ##P < 0.001 compared with hepatocytes incubated with Bt2-cAMP 
alone. (F and G) Ten-week-old C57BL/6J male mice (n = 7 per group) were treated orally with 20 or 50 mg/kg metformin in water or with water 
alone for 5 consecutive days. On the fifth day, mice were fasted for 24 hours and liver was collected 1 hour after metformin administration 
for hepatic ATP, ADP, and AMP determination. (F) Total adenine nucleotide content and (G) AMP/ATP ratios are shown for each condition. 
*P < 0.05, **P < 0.005 compared with vehicle. Data are mean ± SEM.
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Effects of AMPK activators on intracellular ATP content in WT and 
AMPK-KO hepatocytes. After attachment, WT and AMPK-deficient 
primary hepatocytes were cultured for 16 hours in M199 medium con-
taining 100 nM dex. Hepatocytes were then incubated in glucose-free 
DMEM containing lactate/pyruvate (10:1 mM) and 100 nM dex alone 
or with 100 μM Bt2-cAMP and with or without various concentrations of 
metformin, AICAR, or A-769662 as indicated. After 8 hours, cells were 
harvested for ATP content measurement. Results are representative 
of 6 independent experiments. Data are mean ± SEM. §P < 0.001, 
‡P < 0.001 compared with WT and AMPK-KO hepatocytes incu-
bated without Bt2-cAMP; *P < 0.05, **P < 0.001 compared with WT 
hepatocytes incubated with Bt2-cAMP alone; †P < 0.01, ††P < 0.001 
compared with AMPK-KO hepatocytes incubated with Bt2-cAMP alone; 
#P < 0.01 compared with WT hepatocytes incubated under the same 
conditions.
Figure 
Effects of metformin on AMPK activation in WT 
and Lkb1-KO hepatocytes. After attachment, WT 
and LKB1-deficient primary hepatocytes were 
cultured for 16 hours in M199 medium containing 
100 nM dex. Hepatocytes were then incubated in 
glucose-free DMEM containing lactate/pyruvate 
(10:1 mM) and 100 nM dex alone or with 100 μM 
Bt2-cAMP and with or without 0.25, 0.5, 1, or 2 mM 
metformin. After 8 hours, cells were harvested 
for Western blot analysis and measurement of 
LKB1 activity. (A) The level of LKB1 protein was 
assessed by immunoblot analysis using anti-
LKB1 antibodies. β-Actin was immunoblotted 
as a loading control. (B) LKB1 activity was 
assessed following its immunoprecipitation and 
assayed with the LKBtide peptide. Assays were 
performed on hepatocyte extracts from 3 inde-
pendent experiments. (C) Immunoblots were 
performed against phospho-AMPKα (Thr172), 
AMPKα, phospho-ACC (Ser79), ACC, CRTC2, 
G6Pase, and PEPCK. Blots are representative 
of 3 independent experiments.
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Metformin inhibits gluconeogenesis in LKB1-deficient mouse hepatocytes. After attachment, WT and LKB1-deficient primary hepatocytes were 
cultured for 16 hours in M199 medium containing 100 nM dex. Hepatocytes were then incubated in glucose-free DMEM containing lactate/pyruvate 
(10:1 mM) and 100 nM dex alone or with 100 μM Bt2-cAMP and with or without 0.25, 0.5, 1, or 2 mM metformin. After 8 hours, medium was col-
lected for glucose measurement and cells were harvested for ATP content assessment and gluconeogenic gene expression analysis. (A) Glucose 
production was normalized to protein content and expressed as a percentage of glucose produced by WT hepatocytes incubated in the absence of 
both Bt2-cAMP and metformin. Results are representative of 3 independent experiments. (B) Relative mRNA levels of Pgc-1α, Pepck, and G6Pase 
expressed as fold activation relative to levels in WT hepatocytes incubated in the absence of both Bt2-cAMP and metformin. Results are representa-
tive of 3 independent experiments. (C) ATP intracellular content normalized to protein content and expressed as a percentage of WT hepatocyte 
ATP content incubated in the absence of both Bt2-cAMP and metformin. Results are representative of 4 independent experiments. Data are mean 
± SEM. §P < 0.01, ‡P < 0.01 compared with WT and AMPK-KO hepatocytes incubated without Bt2-cAMP; *P < 0.01, †P < 0.01 compared with WT 
and Lkb1-KO hepatocytes incubated with Bt2-cAMP alone; #P < 0.05 compared with WT hepatocytes incubated under the same conditions.
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Forced expression of gluconeogenic genes does not prevent the metformin-induced inhibition of hepatic glucose production. After attachment, 
WT primary hepatocytes were infected with 25 PFU/cell of Ad-GFP or Ad–PGC-1α adenovirus and cultured for 16 hours in M199 medium con-
taining 100 nM dex. Hepatocytes were then incubated in glucose-free DMEM containing lactate/pyruvate (10:1 mM) and 100 nM dex alone or 
with 0.25, 0.5, or 1 mM metformin. After 8 hours, medium was collected for glucose measurement and cells were harvested for Western blot and 
gluconeogenic gene expression analyses and ATP content determination. (A) Relative mRNA levels of Pgc-1α, Pepck, and G6Pase expressed 
as fold activation relative to levels in Ad-GFP–infected hepatocytes. Results represent 3 independent experiments. §P < 0.001 compared with 
Ad-GFP–infected hepatocytes. (B) Immunoblots were performed against PEPCK, G6Pase, phospho-AMPKα (Thr172), AMPKα, phospho-ACC 
(Ser79), and ACC. Blots represent of 3 independent experiments. (C) Glucose production and (D) ATP intracellular content were normalized to 
protein content and expressed as a percentage of that produced by Ad-GFP– or Ad-PGC-1α–infected hepatocytes incubated in the absence 
of metformin. Results represent 5 independent experiments. §P < 0.01 compared with Ad-GFP–infected hepatocytes; #P < 0.05, *P < 0.01, 
**P < 0.001 compared with Ad–PGC-1α–infected hepatocytes incubated in the absence of metformin. Data are mean ± SEM.
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